Search

Displaying results 6241 - 6250 of 10000 in total
  1. Drug

    Allovectin-7

    go.drugbank.com/drugs/DB17439
    Investigational

    It was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207] … Allovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin.

  2. Drug

    6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine

    go.drugbank.com/drugs/DB08099
    Experimental

    This compound belongs to the phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group. This substance targets the protein renin.

  3. Drug

    N-(carboxycarbonyl)-D-phenylalanine

    go.drugbank.com/drugs/DB08263
    Experimental

    This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. … It targets the protein hypoxia-inducible factor 1-alpha inhibitor.

  4. Drug

    (S)-5-(7-(4-(4-Ethyl-4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methylisoxazole

    go.drugbank.com/drugs/DB08725
    Experimental

    This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. This substance targets the protein genome polyprotein.

  5. Drug

    Guanosine

    go.drugbank.com/drugs/DB02857
    Investigational

    Guanosine can be phosphorylated to become GMP (guanosine monophosphate), cGMP (cyclic guanosine monophosphate), GDP (guanosine diphosphate) and GTP (guanosine triphosphate) which are factors in signal … Guanosine is a nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond.

  6. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. … It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass.

  7. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  8. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  9. Drug

    Lotiglipron

    go.drugbank.com/drugs/DB21631
    Investigational

    The usage of the INN stem '-glipron' in the name indicates that Lotiglipron is a glucagon-like peptide 1 receptor (GLPIR) agonist. … Lotiglipron is under investigation in clinical trial NCT05579977 (Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People

  10. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication … It inhibits dopamine release and alters the firing of dopaminergic neurons.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists